| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2021 | Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, ... ... Kassim SH, et al. Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine. PMID 33547459 DOI: 10.1038/s41591-021-01248-2 | 0.517 | |||
| 2018 | Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, ... ... Kassim SH, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine. PMID 29713085 DOI: 10.1038/S41591-018-0010-1 | 0.61 | |||
| 2017 | Xue Q, Bettini E, Paczkowski P, Ng C, Kaiser A, McConnell T, Kodrasi O, Quigley MF, Heath J, Fan R, Mackay S, Dudley ME, Kassim SH, Zhou J. Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response. Journal For Immunotherapy of Cancer. 5: 85. PMID 29157295 DOI: 10.1186/S40425-017-0293-7 | 0.699 | |||
| 2016 | Wang J, Dudley M, Choquette T, Jeschke M, Rutjens E, Kassim S. An Innovative in Vitro Potency Assay Designed to Predict the Fate of Chimeric Antigen Receptors Modified T Cell Therapy Post Infusion in ALL Blood. 128: 5830-5830. DOI: 10.1182/Blood.V128.22.5830.5830 | 0.685 | |||
| 2016 | Xue C, Cerignoli F, Senyukov V, Pierog P, Miller T, Shaw A, Xi B, Muir L, Abassi Y, Kassim S. Abstract B090: Evaluation of a novel impedance-based assay for label free and dynamic assessment of CAR-T constructs efficacy against B-cell leukemia and lymphoma Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B090 | 0.464 | |||
| 2015 | Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ, Hughes MS, Kammula US, Feldman SA, Toomey MA, Kerkar SP, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2278-88. PMID 25695689 DOI: 10.1158/1078-0432.Ccr-14-2085 | 0.67 | |||
| 2015 | Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1019-27. PMID 25538264 DOI: 10.1158/1078-0432.Ccr-14-2708 | 0.732 | |||
| 2015 | Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 540-9. PMID 25154820 DOI: 10.1200/Jco.2014.56.2025 | 0.707 | |||
| 2015 | Tran TH, Scott K, Lee S, Singh R, Cogan S, Bordeaux J, Jennifer H, Lameh J, Tribouley C, Kassim S, Tangri S, Dakappagari N. Quantitative Multiplexed Immunohistochemistry Assays for Exploring CAR Modified T Cells and Checkpoint Inhibitors in Lymphoma Trials Blood. 126: 2659-2659. DOI: 10.1182/Blood.V126.23.2659.2659 | 0.504 | |||
| 2015 | Beane JD, Lee G, Zheng Z, Gandhi N, Abate-Daga D, Bharathan M, Black M, Mendel M, Yu Z, Kassim SH, Chandran S, Giedlin MA, Ando D, Rebar E, Reik A, et al. 77. Clinical Scale Zinc Finger Nuclease (ZFN)-Driven Gene-Editing of PD-1 in Tumor Infiltrating Lymphocytes (TIL) for the Potential Treatment of Metastatic Melanoma Molecular Therapy. 23: S33-S34. DOI: 10.1016/S1525-0016(16)33682-6 | 0.608 | |||
| 2014 | Better M, Pugach O, Lu L, Somerville R, Kassim S, Kochenderfer J, Rosenberg SA, Marshall MA, Bot A, Nolop KB, Roberts M, Feldman S. Rapid cell expansion (RACE) technology for production of engineered autologous T-cell therapy: Path toward manageable multicenter clinical trials in aggressive NHL with anti-CD19 CAR. Journal of Clinical Oncology. 32: 3079-3079. DOI: 10.1200/Jco.2014.32.15_Suppl.3079 | 0.607 | |||
| 2014 | Beane JD, Lee GK, Zheng Z, Gandhi N, Abate-Daga D, Bharathan M, Black M, Mendel M, Yu Z, Kassim SH, Chandran S, Giedlin M, Ando D, Rebar E, Reik A, et al. Clinical scale zinc finger nuclease (ZFN)-driven gene-editing of PD-1 in tumor infiltrating lymphocytes (TIL) for the potential treatment of metastatic melanoma Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P2 | 0.444 | |||
| 2013 | Chen SJ, Sanmiguel J, Lock M, McMenamin D, Draper C, Limberis MP, Kassim SH, Somanathan S, Bell P, Johnston JC, Rader DJ, Wilson JM. Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemia. Human Gene Therapy. Clinical Development. 24: 154-60. PMID 24070336 DOI: 10.1089/Humc.2013.082 | 0.547 | |||
| 2013 | Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 122: 4129-39. PMID 24055823 DOI: 10.1182/Blood-2013-08-519413 | 0.716 | |||
| 2013 | Kassim SH, Jordan J, Schreiter J, Adhikarakunnathu S, Baribaud F, San Mateo L. Systematic identification of novel SLE related autoantibodies responsible for type I IFN production in human plasmacytoid dendritic cells. Cellular Immunology. 284: 119-28. PMID 23973875 DOI: 10.1016/J.Cellimm.2013.07.017 | 0.323 | |||
| 2013 | Kassim SH, Somerville RP. From lipoproteins to chondrocytes: a brief summary of the European Medicines Agency's regulatory guidelines for advanced therapy medicinal products. Human Gene Therapy. 24: 568-70. PMID 23777464 DOI: 10.1089/Hum.2013.101 | 0.324 | |||
| 2013 | Kassim SH, Li H, Bell P, Somanathan S, Lagor W, Jacobs F, Billheimer J, Wilson JM, Rader DJ. Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia. Human Gene Therapy. 24: 19-26. PMID 22985273 DOI: 10.1089/Hum.2012.108 | 0.559 | |||
| 2013 | Kochenderfer JN, Dudley ME, Kassim SH, Carpenter RO, Yang JC, Phan GQ, Hughes MS, Sherry RM, Feldman S, Spaner D, Nathan DN, Morton KE, Toomey MA, Rosenberg SA. Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor Blood. 122: 168-168. DOI: 10.1182/Blood.V122.21.168.168 | 0.72 | |||
| 2013 | Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford W, Hakim FT, Halverson D, Fowler DH, Hardy NM, Mato A, Hickstein DD, Gea-Banacloche J, Pavletic SZ, Sportes C, et al. Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation Blood. 122: 151-151. DOI: 10.1182/Blood.V122.21.151.151 | 0.722 | |||
| 2011 | Kassim SH, Vandenberghe LH, Hovhannisyan R, Wilson JM, Rader DJ. Identification and functional characterization in vivo of a novel splice variant of LDLR in rhesus macaques. Physiological Genomics. 43: 911-6. PMID 21628398 DOI: 10.1152/Physiolgenomics.00006.2011 | 0.69 | |||
| 2010 | Kassim SH, Wilson JM, Rader DJ. Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies. Clinical Lipidology. 5: 793-809. PMID 22505953 DOI: 10.2217/Clp.10.73 | 0.51 | |||
| 2010 | Kassim SH, Li H, Vandenberghe LH, Hinderer C, Bell P, Marchadier D, Wilson A, Cromley D, Redon V, Yu H, Wilson JM, Rader DJ. Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. Plos One. 5: e13424. PMID 20976059 DOI: 10.1371/Journal.Pone.0013424 | 0.703 | |||
| 2009 | Rajasagi NK, Kassim SH, Kollias CM, Zhao X, Chervenak R, Jennings SR. CD4+ T cells are required for the priming of CD8+ T cells following infection with herpes simplex virus type 1. Journal of Virology. 83: 5256-68. PMID 19279095 DOI: 10.1128/Jvi.01997-08 | 0.682 | |||
| 2009 | Kassim SH, Rajasagi NK, Ritz BW, Pruett SB, Gardner EM, Chervenak R, Jennings SR. Dendritic cells are required for optimal activation of natural killer functions following primary infection with herpes simplex virus type 1. Journal of Virology. 83: 3175-86. PMID 19144708 DOI: 10.1128/Jvi.01907-08 | 0.64 | |||
| 2008 | Nogusa S, Ritz BW, Kassim SH, Jennings SR, Gardner EM. Characterization of age-related changes in natural killer cells during primary influenza infection in mice. Mechanisms of Ageing and Development. 129: 223-30. PMID 18304606 DOI: 10.1016/J.Mad.2008.01.003 | 0.604 | |||
| 2006 | Kassim SH, Rajasagi NK, Zhao X, Chervenak R, Jennings SR. In vivo ablation of CD11c-positive dendritic cells increases susceptibility to herpes simplex virus type 1 infection and diminishes NK and T-cell responses. Journal of Virology. 80: 3985-93. PMID 16571815 DOI: 10.1128/Jvi.80.8.3985-3993.2006 | 0.651 | |||
| Show low-probability matches. | |||||